Therapeutics involved in managing initial and recurrent Clostridium difficile infection:An updated literature review  

作　　者：Vignesh K Nagesh Hadrian Hoang-Vu Tran Daniel Elias Izage Kianifar Aguilar Tanni Sethi AiswaryaMenon Charlene Mansour Florchi Furman Kylie Tsotsos Talia Subar Auda Auda Aman Sidiqui JevonLamar Nikita Wadhwani Shraboni Dey Abraham Lo Adam Atoot Simcha Weissman Humberto Sifuentes Ayrton I Bangolo 

机构地区：[1]Department of Internal Medicine,Hackensack Palisades Medical Center,North Bergen,NJ 07047,United States [2]Department of Gastroenterology,Augusta University,Augusta,GA 30912,United States

出　　处：《World Journal of Gastrointestinal Pharmacology and Therapeutics》2024年第5期1-14,共14页世界胃肠药理与治疗学杂志（英文版）（电子版）

摘　　要：Clostridium difficile infection(CDI)has been increasing due to the effect of recurrent hospitalizations.The use of antibiotics has been shown to alter the gut microbiome and lead to CDIs.The treatment is limited to three major antibiotics;however,the incidence of recurrent CDIs has been increasing and drug resistance is a major concern.This aspect is a growing concern in modern medicine especially in the elderly population,critical care patients,and immunocompromised individuals who are at high risk of developing CDIs.Clostridium difficile can lead to various complications including septic shock and fulminant colitis that could prove to be lethal in these patients.Newer modalities of treatment have been developed including bezlotoxumab,a monoclonal antibody and fecal microbiota transplant.There have been studies showing asymptomatic carriers and drug resistance posing a major threat to the healthcare system.Newer treatment options are being studied to treat and prevent CDIs.This review will provide an insight into the current treatment modalities,prevention and newer modalities of treatment and challenges faced in the treatment of CDIs.

关 键 词：Clostridium difficile ANTIBIOTICS VANCOMYCIN Fidaxomicin Prevention Bezlotoxumab Fecal microbiota transplant 

分 类 号：R576[医药卫生—消化系统] R582.1[医药卫生—内科学]